Bioxodes atteint un premier objectif de recrutement pour l'essai de phase 2a sur l'hémorragie intracérébrale
19. Dezember 2024 02:30 ET
|
Bioxodes
Bioxodes a recruté les 16 premiers patients pour l'essai de BIOX-101Une analyse intermédiaire sera réalisée à la fin du traitement de la première cohorte de patientsBIOX-101 est un candidat...
Bioxodes meets enrollment milestone in Phase 2a intracerebral hemorrhagic stroke trial
19. Dezember 2024 02:30 ET
|
Bioxodes
Bioxodes has enrolled first 16 patients in trial with BIOX-101Completing treatment of first cohort of patients will trigger interim analysisBIOX-101 is a first-in-class drug candidate, a peptide...
[Latest] Global Injectable Drug Delivery Devices Market Size/Share Worth USD 40,956.3 Million by 2033 at a 10.21% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
25. November 2024 11:30 ET
|
Custom Market Insights
Austin, TX, USA, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Injectable Drug Delivery Devices Market Size, Trends and Insights By Device Type...
[Latest] Global Embolic Protection Device Market Size/Share Worth USD 3,562.2 Million by 2033 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
28. Oktober 2024 22:00 ET
|
Custom Market Insights
Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Embolic Protection Device Market Size, Trends and Insights By Type of Device...
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024
15. Oktober 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
11. Oktober 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress
E-Star BioTech Set to Initiate Phase 2 Clinical Trial of MANP in Resistant Hypertension With Support of Latest Investment
08. Oktober 2024 09:00 ET
|
E-Star Biotech
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney...
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
08. Oktober 2024 07:30 ET
|
Tourmaline Bio, Inc.
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
Orphan Drugs Market Size & Share to Surpass USD 424.0 billion by 2034, Rising a CAGR 6.9% | Analysis by Transparency Market Research, Inc.
26. September 2024 07:14 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The orphan drugs market (희귀의약품 시장) was worth US$ 195.0 billion in 2023. The market is...
OMEICOS Therapeutics Completes Enrollment of PMD-OPTION Study in Primary Mitochondrial Disease
26. September 2024 06:00 ET
|
OMEICOS Therapeutics GmbH
Interim data confirms OMT-28’s strong safety profile in PMD patients, top-line data expected mid-2025 BERLIN, GERMANY, September 26, 2024 – OMEICOS, a biopharmaceutical company developing...